Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy - A Single Arm, Phase 1b/2, Multicenter Study

NCT05990543 is registered in ClinicalTrials.gov with Korea University Anam Hospital as lead sponsor.

NCT NCT05990543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05990543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy - A Single Arm, Phase 1b/2, Multicenter Study
Lead sponsor
Korea University Anam Hospital
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 29, 2024
Completion date
December 31, 2026
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic colorectal cancer